Altair Pereira de Melo Neto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Altair Pereira de Melo Neto has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Karlos Daniell Araújo dos Santos
Universidade Federal de Roraima, Brasil
3 shared publications - Carlos Henrique de Oliveira Ferreira
Federal University of Paraiba , Joao Pessoa , Paraiba, Brazil , ufpb.br
2 shared publications - Hilária Saugo Faria
Universidade Federal de Santa Maria Escola de Medicina Santa Maria Rio Grande do Sul Brazil Escola de Medicina, Universidade Federal de Santa Maria, Santa Maria, Rio Grande do Sul, Brazil
2 shared publications - Lucas Cael Azevedo Ramos Bendaham
Universidade Federal de Roraima, Boa Vista, RR, Brazil
2 shared publications - Marcela da Silva Kazitani Cunha
Faculty of Medicine of Marília, Marília, Brazil
2 shared publications - Milene Vitória Sampaio Sobral
University of Western São Paulo, Presidente Prudente, Brazil
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Anesthesiology Research and Practice
- Vol. 2026 (1) , 5856805
Effect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.
- 1 January 2026
- Published by Wiley in Anesthesiology Research and Practice
- Vol. 2026 (1) , 5856805
Open AccessEffect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.
- 1 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108356
Efficacy and safety of mepolizumab for eosinophilic chronic obstructive pulmonary disease: A systematic review and meta-analysis
- 1 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108356
Efficacy and safety of mepolizumab for eosinophilic chronic obstructive pulmonary disease: A systematic review and meta-analysis
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3444-3455
Effect of Diabetes Mellitus on Clinical Outcomes After Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta‐Analysis
Transcatheter Aortic Valve Implantation (TAVI) or Replacement (TARV) is a widely established treatment for symptomatic severe aortic stenosis (AS) in patients with high or intermediate surgical risk. Diabetes mellitus (DM) is prevalent in TAVR patients and is associated with an increased risk of cardiovascular events, which may elevate procedural risks. A systematic review and meta‐analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Cochrane databases were searched. A random‐effects model was applied, with 95% confidence intervals (CIs) and a 5% significance level. Statistical analyses were performed using RStudio version 4.4.1. Twelve studies with 214,444 patients were included, comprising 74,294 diabetic and 140,150 nondiabetic individuals. The analysis revealed no significant differences in all‐cause mortality, procedure mortality, 30‐day mortality, or complications such as bleeding, myocardial infarction, and major complications. However, 1‐year mortality was significantly higher in the diabetic group (RR: 1.51, 95% CI: 1.08–2.13). Diabetic patients were at higher risk for renal injury (RR: 1.46, 95% CI: 1.40–1.51) and lower risk of stroke (RR: 0.91, 95% CI: 0.83–0.99). The length of hospital stay and other major complications showed no significant differences. There was an increased risk of 1‐year mortality and renal injury in diabetic patients undergoing TAVI compared to non‐diabetics. Surprisingly, the risk for developing stroke in the diabetic group was significantly lower. In any case, the study emphasizes the need for tighter DM control to decrease the risk of such complications in the future.
- 23 September 2025
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 106 (7) , 3444-3455
Effect of Diabetes Mellitus on Clinical Outcomes After Transcatheter Aortic Valve Implantation: An Updated Systematic Review and Meta‐Analysis
Transcatheter Aortic Valve Implantation (TAVI) or Replacement (TARV) is a widely established treatment for symptomatic severe aortic stenosis (AS) in patients with high or intermediate surgical risk. Diabetes mellitus (DM) is prevalent in TAVR patients and is associated with an increased risk of cardiovascular events, which may elevate procedural risks. A systematic review and meta‐analysis were conducted following PRISMA guidelines. PubMed, Web of Science, and Cochrane databases were searched. A random‐effects model was applied, with 95% confidence intervals (CIs) and a 5% significance level. Statistical analyses were performed using RStudio version 4.4.1. Twelve studies with 214,444 patients were included, comprising 74,294 diabetic and 140,150 nondiabetic individuals. The analysis revealed no significant differences in all‐cause mortality, procedure mortality, 30‐day mortality, or complications such as bleeding, myocardial infarction, and major complications. However, 1‐year mortality was significantly higher in the diabetic group (RR: 1.51, 95% CI: 1.08–2.13). Diabetic patients were at higher risk for renal injury (RR: 1.46, 95% CI: 1.40–1.51) and lower risk of stroke (RR: 0.91, 95% CI: 0.83–0.99). The length of hospital stay and other major complications showed no significant differences. There was an increased risk of 1‐year mortality and renal injury in diabetic patients undergoing TAVI compared to non‐diabetics. Surprisingly, the risk for developing stroke in the diabetic group was significantly lower. In any case, the study emphasizes the need for tighter DM control to decrease the risk of such complications in the future.
- Open Access
- 5 July 2025
- Published by Elsevier in Brazilian Journal of Anesthesiology (English Edition)
- Vol. 75 (6) , 844659
Respiratory outcomes of adrenergic beta-antagonists in patients undergoing tracheal extubation: a systematic review and meta-analysis of randomized controlled trials
- 5 July 2025
- Published by Elsevier in Brazilian Journal of Anesthesiology (English Edition)
- Vol. 75 (6) , 844659
Open AccessRespiratory outcomes of adrenergic beta-antagonists in patients undergoing tracheal extubation: a systematic review and meta-analysis of randomized controlled trials
- Open Access
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (08) , 001-008
Corticotherapy versus adrenocorticotropic hormone for treating West syndrome: a systematic review and meta-analysis
Although it is known that the most commonly used therapies for West syndrome (WS) are intramuscular adrenocorticotropic hormone (ACTH) and oral prednisolone, there is still controversy in the literature regarding the equivalence of their effects.We aimed to present an updated review comparing the therapeutic and adverse effects of ACTH therapy versus corticosteroids in children with West syndrome (WS).The PubMed, EMBASE, and Cochrane Central databases were searched. The outcomes of interest selected were spasm cessation on day 14 of therapy, cessation of hypsarrhythmia and adverse effects such as weight gain, infection, irritability, and hypertension. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a meta-analysis was performed. We compared the results using the risk ratio (RR) and odds ratio (OR). for the binary outcomes, with 95% confidence intervals (CI) and a random-effects model. Statistical analysis was performed using RevMan 5.1.7.Compared with corticoids, ACTH was associated with a significant increase in weight (RR: 1.41; 95% CI: 1.01–1.97; p = 0.04). There was no significant difference in cessation of spasms on day 14 (OR: 0.91; 95% CI: 0.47–1.47; p = 0.79), hypsarrhythmia (OR: 0.97; 95% CI: 0.22–4.34), irritability (RR: 0.78; 95% CI: 0.30–1.99), hypertension (RR: 0.64; 95% CI: 0.35–1.15; p = 0.14), and infection (RR: 0.69; 95% CI: 0.19–2.50; p = 0.57).This study provides robust evidence regarding the safety and efficacy of ACTH or corticoids in children with WS. However, the significant heterogeneity between studies restricts the analysis, emphasizing the need for additional research to assess the best WS treatment option.
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (08) , 001-008
Open AccessCorticotherapy versus adrenocorticotropic hormone for treating West syndrome: a systematic review and meta-analysis
Although it is known that the most commonly used therapies for West syndrome (WS) are intramuscular adrenocorticotropic hormone (ACTH) and oral prednisolone, there is still controversy in the literature regarding the equivalence of their effects.We aimed to present an updated review comparing the therapeutic and adverse effects of ACTH therapy versus corticosteroids in children with West syndrome (WS).The PubMed, EMBASE, and Cochrane Central databases were searched. The outcomes of interest selected were spasm cessation on day 14 of therapy, cessation of hypsarrhythmia and adverse effects such as weight gain, infection, irritability, and hypertension. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, and a meta-analysis was performed. We compared the results using the risk ratio (RR) and odds ratio (OR). for the binary outcomes, with 95% confidence intervals (CI) and a random-effects model. Statistical analysis was performed using RevMan 5.1.7.Compared with corticoids, ACTH was associated with a significant increase in weight (RR: 1.41; 95% CI: 1.01–1.97; p = 0.04). There was no significant difference in cessation of spasms on day 14 (OR: 0.91; 95% CI: 0.47–1.47; p = 0.79), hypsarrhythmia (OR: 0.97; 95% CI: 0.22–4.34), irritability (RR: 0.78; 95% CI: 0.30–1.99), hypertension (RR: 0.64; 95% CI: 0.35–1.15; p = 0.14), and infection (RR: 0.69; 95% CI: 0.19–2.50; p = 0.57).This study provides robust evidence regarding the safety and efficacy of ACTH or corticoids in children with WS. However, the significant heterogeneity between studies restricts the analysis, emphasizing the need for additional research to assess the best WS treatment option.